Finance

Lists
Why is 4142 down 6,62%?
Dive Deeper
4142:TPE
Adimmune Corp
14,80 TWD
-6,62%
(-1,05) 1D
20-ноя., 13:30:09 GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 4142...
Open
15,75 TWD
High
15,75 TWD
Low
14,80 TWD
Mkt. cap
6,36 млд
Avg. vol.
1,13 млн
Volume
1,63 млн
P/E ratio
85,76
52-wk high
21,50 TWD
52-wk low
14,80 TWD
EPS
0,17 TWD
Shares outstanding
235,29 млн
No. of employees
564
Open
15,75 TWD
High
15,75 TWD
Low
14,80 TWD
Mkt. cap
6,36 млд
Avg. vol.
1,13 млн
Volume
1,63 млн
P/E ratio
85,76
52-wk high
21,50 TWD
52-wk low
14,80 TWD
EPS
0,17 TWD
Shares outstanding
235,29 млн
No. of employees
564
News stories
From web sources and news partners
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
Industry-
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
745,46 млн
82,32 млн
66,76 млн
715,67 млн
Cost of goods sold
376,00 млн
156,87 млн
129,59 млн
413,47 млн
Cost of revenue
376,00 млн
156,87 млн
129,59 млн
413,47 млн
Research and development expenses
74,68 млн
45,44 млн
30,55 млн
27,96 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94,80 млн
79,22 млн
79,34 млн
84,37 млн
Operating expense
197,18 млн
124,66 млн
109,88 млн
112,33 млн
Total operating expenses
573,18 млн
281,54 млн
239,47 млн
525,80 млн
Operating income
172,28 млн
-199,22 млн
-172,71 млн
189,87 млн
Other non operating income
10,40 млн
710,00 миң
2,18 млн
2,03 млн
EBT including unusual items
200,77 млн
-200,47 млн
-172,95 млн
185,53 млн
EBT excluding unusual items
200,30 млн
-198,95 млн
-172,95 млн
185,53 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
220,42 млн
-185,54 млн
-160,23 млн
198,10 млн
Net profit margin
29,57%
-225,41%
-240,02%
27,68%
Earnings per share
-
-
-
0,47
Interest and investment income
9,92 млн
3,10 млн
6,47 млн
3,04 млн
Interest expense
-10,40 млн
-7,40 млн
-6,95 млн
-9,42 млн
Net interest expenses
-475,00 миң
-4,30 млн
-480,00 миң
-6,38 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
219,90 млн
-156,74 млн
-128,36 млн
266,40 млн
Gain or loss from assets sale
-3,00 миң
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору